A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.

导出 LinkOut

翻译打印收藏纠错

第一作者： Alan J,Kivitz

第一单位： Altoona Center for Clinical Research, 175 Meadowbrook Lane, PO Box 1018, Duncansville, PA 16635, USA.

作者： Alan J,Kivitz ^[1] ; Stanley,Cohen ^[2] ; Edward,Keystone ^[3] ; Ronald F,van Vollenhoven ^[4] ; Boulos,Haraoui ^[5] ; Jeffrey,Kaine ^[6] ; Haiyun,Fan ^[7] ; Carol A,Connell ^[8] ; Eustratios,Bananis ^[9] ; Liza,Takiya ^[10] ; Roy,Fleischmann ^[2]

作者单位： Altoona Center for Clinical Research, 175 Meadowbrook Lane, PO Box 1018, Duncansville, PA 16635, USA. ^[1] Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX 75231, USA. ^[2] Mount Sinai Hospital, 600 University Ave, Toronto, ON M5G 1X5, Canada. ^[3] Amsterdam Rheumatology and Immunology Center, 1007 MB Amsterdam, The Netherlands. ^[4] Institut de Rhumatologie de Montréal, 1551, rue Ontario Est, Montréal, QC H2L 1S6, Canada. ^[5] Sarasota Arthritis Research Center, 1945 Versailles St, Sarasota, FL 34239, USA. ^[6] Pfizer Inc, 500 Arcola Rd, F5352, Collegeville, PA 19426, USA. ^[7] Pfizer Inc, 558 Eastern Point Rd, Groton, CT 06340, USA. ^[8] Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA. ^[9] Pfizer Inc, 500 Arcola Rd, F5352, Collegeville, PA 19426, USA. Electronic address: liza.takiya@pfizer.com. ^[10]

关键词 Combination therapy Keywords Monotherapy ORAL Scan (NCT00847613)ORAL Solo (NCT00814307)ORAL Start (NCT01039688)ORAL Step (NCT00960440)ORAL Sync (NCT00856544)Rheumatoid arthritis Safety Tofacitinib and ORAL Standard (NCT00853385)